These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16670649)

  • 1. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD?
    Spencer TJ; Faraone SV; Biederman J; Lerner M; Cooper KM; Zimmerman B;
    J Am Acad Child Adolesc Psychiatry; 2006 May; 45(5):527-537. PubMed ID: 16670649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder.
    Pliszka SR; Matthews TL; Braslow KJ; Watson MA
    J Am Acad Child Adolesc Psychiatry; 2006 May; 45(5):520-526. PubMed ID: 16670648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health.
    Moungnoi P; Maipang P
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S158-63. PubMed ID: 22043770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight, Height, and Body Mass Index in Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate.
    Díez-Suárez A; Vallejo-Valdivielso M; Marín-Méndez JJ; de Castro-Manglano P; Soutullo CA
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):723-730. PubMed ID: 28817309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
    Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH
    Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylphenidate and atomoxetine treatment negatively affect physical growth indexes of school-age children and adolescents with attention-deficit/hyperactivity disorder.
    Deng L; Zhou P; Zhu L; Zhang Y; Yang T; Zhao Q; Chen J; Li T; Cheng Q; Chen L
    Pharmacol Biochem Behav; 2021 Sep; 208():173225. PubMed ID: 34217783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of Methylphenidate Treatment on Child Growth in Thai Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Koonrungsesomboon K; Koonrungsesomboon N
    J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):189-197. PubMed ID: 31841645
    [No Abstract]   [Full Text] [Related]  

  • 9. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH.
    Hoare P; Remschmidt H; Medori R; Ettrich C; Rothenberger A; Santosh P; Schmit M; Spender Q; Tamhne R; Thompson M; Tinline C; Trott GE
    Eur Child Adolesc Psychiatry; 2005 Sep; 14(6):305-9. PubMed ID: 16220214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study.
    Remschmidt H; Hoare P; Ettrich C; Rothenberger A; Santosh P; Schmidt M; Spender Q; Tamhne R; Thompson M; Tinline C; Trott GE; Medori R
    Eur Child Adolesc Psychiatry; 2005 Sep; 14(6):297-304. PubMed ID: 16220213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy.
    Palumbo D; Spencer T; Lynch J; Co-Chien H; Faraone SV
    J Child Adolesc Psychopharmacol; 2004; 14(2):185-94. PubMed ID: 15319016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy.
    Schneider G; Banaschewski T; Feldman BL; Gustafsson PA; Murphy B; Reynolds M; Coghill DR; Spalding WM
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):285-304. PubMed ID: 30942617
    [No Abstract]   [Full Text] [Related]  

  • 13. [Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD].
    Heger S; Trott GE; Meusers M; Schulz E; Rothenberger A; Rettig K; Medori R; Schreiner A; Remschmidt H;
    Z Kinder Jugendpsychiatr Psychother; 2006 Jul; 34(4):257-65. PubMed ID: 16927568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.
    Wilens T; Pelham W; Stein M; Conners CK; Abikoff H; Atkins M; August G; Greenhill L; McBurnett K; Palumbo D; Swanson J; Wolraich M
    J Am Acad Child Adolesc Psychiatry; 2003 Apr; 42(4):424-33. PubMed ID: 12649629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication.
    Schertz M; Adesman AR; Alfieri NE; Bienkowski RS
    Pediatrics; 1996 Oct; 98(4 Pt 1):763-9. PubMed ID: 8885958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of methylphenidate on height and weight in Korean children and adolescents with attention-deficit/hyperactivity disorder: a retrospective chart review.
    Kim HW; Kim SO; Shon S; Lee JS; Lee HJ; Choi JH
    J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):448-53. PubMed ID: 25285915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth and pubertal development of adolescent boys on stimulant medication for attention deficit hyperactivity disorder.
    Poulton AS; Melzer E; Tait PR; Garnett SP; Cowell CT; Baur LA; Clarke S
    Med J Aust; 2013 Jan; 198(1):29-32. PubMed ID: 23330767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.